Cardiac Insight's Heart@Home ECG Test Kit can help address new telehealth demands placed on cardiology practices by the COVID-19 response using arrhythmia diagnosis technology of the wearable Cardea Solo Sensor.

Cardiac Insight's [email protected] ECG Test Kit can help address new telehealth demands placed on cardiology practices by the COVID-19 response using arrhythmia diagnosis technology of the wearable Cardea Solo Sensor. 

News | ECG Wireless Remote Access | May 04, 2020
May 4, 2020 — Cardiac Insight Inc., a U.S.-based digital healthcare innovator specializing in body-worn sensor...
Abiomed Adds ECMO Cardiopulmonary Support to its Portfolio with the purchase of Breethe. The Breethe ECMO system. Abiomed invested in Breethe in mid-2019. Breethe has applied for 510(k) clearance by the Food and Drug Administration (FDA).

The Breethe ECMO system. Abiomed invested in Breethe in mid-2019. Breethe has applied for 510(k) clearance by the Food and Drug Administration (FDA).

News | ECMO Systems | May 01, 2020
May 1, 2020 — Abiomed, maker of the Impella heart pump, has acquired Breethe, developer of a novel extracorporeal...
Videos | Coronavirus (COVID-19) | May 01, 2020
Thomas Maddox, M.D., MSc, FACC, the chair of the American College of Cardiology (ACC) Science and Quality Committee,...
Feature | Cardiovascular Information Systems (CVIS) | May 01, 2020 | Dave Fornell, Editor
According to the healthcare IT market research firm KLAS, adopting structured reporting is top of mind in the...
Childhood Obesity and High Blood Pressure Warn of Future Heart Disease. Vivian Fornell playing doctor at the Elgin Public Library. Photo by Dave Fornell
News | Hypertension | April 30, 2020
April 30, 2020 — A large study in adolescents and children, some as young as 3 years of age, shows a link between...
An example of strain imaging cardiac echocardiography software offered on Canon's cardiac ultrasound systems. It is highly automated to speed workflow. It color codes areas of different strain values, graphs these in a visual plot and pulls quantification measurements. Photo by Dave Fornell.

An example of strain imaging cardiac echocardiography software offered on Canon's cardiac ultrasound systems. It is highly automated to speed workflow. It color codes areas of different strain values, graphs these in a visual plot and pulls quantification measurements. Photo by Dave Fornell.

Feature | Cardiovascular Ultrasound | April 30, 2020 | Dave Fornell, Editor
The biggest trend across healthcare the past two years is the emergence of artificial intelligence (AI) and its...
360 Photos | 360 View Photos | April 30, 2020
This is a human cadaver heart being examined by a high school student as part of a science education program offered by...
EP lab photo from Philips Healthcare
News | EP Lab | April 30, 2020
May 1, 2020 — The Heart Rhythm Society (HRS) has created a COVID-19 Task Force to make recommendations related to...
#COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2 Pulmonary CT angiography of a 68 year old male. The CT scan was obtained 10 days after the onset of COVID-19 symptoms and on the day the patient was transferred to the intensive care unit.

Figure 2: Pulmonary CT angiography of a 68 year old male. The CT scan was obtained 10 days after the onset of COVID-19 symptoms and on the day the patient was transferred to the intensive care unit. Axial CT images (lung windows) (a,b) show peripheral ground-glass opacities (arrow) associated with areas of consolidation in dependent portions of the lung (arrowheads). Interlobular reticulations, bronchiectasis (black arrow) and lung architectural distortion are present. Involvement of the lung volume was estimated to be between 25% and 50%. Coronal CT reformations (mediastinum windows) (c,d) show bilateral lobar and segmental pulmonary embolism (black arrows). Courtesy of RSNA

News | Coronavirus (COVID-19) | April 30, 2020
April 23, 2020 — A special report published in the journal Radiology outlines prevention, diagnosis and treatment of...
There have been several safety reports to the FDA that COVID-19 patients receiving hydroxychloroquine and chloroquine, either aloneaths and Injuries From Use of Antimalarial Drugs in COVID-19 Patients. he U.S. Food and Drug Administration (FDA) issued a Drug Safety Communication today reminding doctors there are serious side effects when using hydroxychloroquine and chloroquine in the off-lable use to treat COVID-19 patients. This includes potentially life-threatening heart rhythms. #COVID19 #SARScov2

There have been several safety reports to the FDA that COVID-19 patients receiving hydroxychloroquine and chloroquine, either alone or combined with azithromycin or other QT prolonging medicines, have caused serious These adverse events, including death. Events reported included QT interval prolongation, ventricular tachycardia and ventricular fibrillation.

Feature | Coronavirus (COVID-19) | April 24, 2020 | Dave Fornell, Editor
April 23, 2020 — The U.S. Food and Drug Administration (FDA) issued a Drug Safety Communication today reminding doctors...
AliveCor and Omron are partnering to integrate Alivecor's mobile device ECG technology with Omron's wireless blood pressure monitoring technology on Remote Cardiovascular Monitoring into one platform for remote patient monitoring.

AliveCor and Omron are partnering to integrate Alivecor's mobile device ECG technology with Omron's wireless blood pressure monitoring technology on Remote Cardiovascular Monitoring into one platform for remote patient monitoring.

News | Remote Monitoring | April 24, 2020
April 24, 2020 — AliveCor and Omron Healthcare announced a global, strategic alliance that combines AliveCor's mobile...
The U.S. Food and Drug Administration (FDA) has lifted its injunction prohibiting the manufacturing and shipping of external defibrillator AEDs in the United States. 
News | Defibrillator Monitors | April 24, 2020
April 24, 2020 — The U.S. Food and Drug Administration (FDA) has lifted its injunction prohibiting the manufacturing...
LivaNova Modifies its ECMO Indications Beyond Six Hours to Address COVID-19. The FDA expanded the use indications for ECMO systems April 6 so tthey can be used beyond six hours and for use in COVID-19 patients in need of circulatory and pulmonary support.

The FDA expanded the use indications for ECMO systems April 6 so the systems can be used beyond six hours and for use in COVID-19 patients in need of circulatory and pulmonary support. Image shows an ECMO team at work at Tufts Medical Center in Boston in December 2019. Photo by Dave Fornell

News | Coronavirus (COVID-19) | April 23, 2020
April 23, 2020 – LivaNova PLC said the U.S. Food and Drug Administration (FDA) is now permitting the company to expand...
Videos | Coronavirus (COVID-19) | April 22, 2020
Ehtisham Mahmud, M.D., FSCAI, president of the Society for Cardiovascular Angiography and Interventions (SCAI) and...
SCAI, ACC and ACEP release consensus document on how to manage acute myocardial infarctions during the SARS-C0V-2 outbreak, #COVIF19 #coronavirus
Feature | Cath Lab | April 22, 2020
April 22, 2020 — The Society for Cardiovascular Angiography and Interventions (SCAI), along with the American College...